Study On Cardiotoxicity Of Trastuzumab In Patients With HER-2 Positive Breast Cancer

Objective:Trastuzumab is a highly effective and selective targeted therapy for human epidermal growth factor receptor 2(HER-2)positive breast cancer.However,the cardiotoxicity caused by trastuzumab may limit its application in among the some breast cancer patients.Therefore,This paper discusses the occurrence and related risk factors of cardiactoxicity in patients with HER-2 positive breast cancer treated with trastuzumab.Methods:We collected the data of HER-2 positive breast cancer patients(n =106)who received trastuzumab treatment in the Department of Mammary Gland of the First Affiliated Hospital of Xinjiang Medical University from January 2015 to September2020.The collected data included basic data of HER-2 positive breast cancer patients,ventricular ejection fraction(LVEF)level before and after trastuzumab administration,ecg results,etc.Results:After receiving trastuzumab treatment,26(24.5%)patients had EF decline ≥10%,in between 6(5.7%)patientshad EF decline ≥20%.trastuzumab was discontinued due to suspected cardiotoxicity in 1(0.9%)patients.In addition,54(50.9%)patients in the collected data showed abnormal ECG manifestations.During trastuzumab treatment,19(17.9%)patients developed symptoms that might be related to cardiotoxicity.Factors such as advanced age(≥55 years),postmenopausal,and anthracyclines in treatment regimens significantly increased the risk of trastuzumab-induced cardiotoxicity in patients with HER-2 positive breast cancer(P<0.05).Conclusions:Cardiotoxicity has been recognized as a very common adverse effect of trastuzumab,occurring in >10% in patients with HER-2 positive breast cancer receiving trastuzumab treatment.Therefore,it is necessary to monitor cardiac function in trastuzumab-treated HER-2 positive breast cancer patients in order to further improve the safe use of trastuzumab and to manage adverse events of this potential cardiotoxicity.